Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations

Mattía Galli(Maria Cecilia Hospital), Dominick J. Angiolillo(University of Florida), Fabiana Rollini(Florida College), Filippo Crea(Università Cattolica del Sacro Cuore), Francesco Franchi(Florida College), Larisa H. Cavallari(University of Florida), Davide Capodanno(University of Catania)
Expert Review of Clinical Pharmacology
May 15, 2021
10.1080/17512433.2021.1927709
Cited by 49

Related Papers

2024 ESC Guidelines for the management of chronic coronary syndromes
|European Heart Journal|2024|2.3k
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|877
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
|New England Journal of Medicine|2013|825
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38
|Circulation|2008|757
Platelet Inhibition with Cangrelor in Patients Undergoing PCI
|New England Journal of Medicine|2009|618